Organon Pharma Pty

Company snapshot

At Organon, we believe in a better and healthier every day for every woman. And we understand that women are foundational to a healthier world. As a company, we are trying to listen to women’s healthcare needs, big and small, develop treatments tailored to them — because we know there is so much more we can do for women and their health.

• 5 approved product(s) across US/EU regulatory metadata.
• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Organon Pharma Pty. Not investment advice.

• approval Jun 2, 2026

  Organon (OGN) to be Acquired by Sun Pharma for $14.00 Cash per Share

Recent activity

Latest pipeline, patent, and corporate events for Organon Pharma Pty.

1. May 26, 2026 Clinical update

   E6005 — Phase 2

View all clinical trial activity →

• What is Organon Pharma Pty?

  Organon Asia Pacific is a pharma organization headquartered in SG. Primary therapeutic focus areas include Atopic Dermatitis. NovaPharmaNews links 1 clinical program(s), 6 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO s

• Is Organon Pharma Pty publicly traded?

  Organon Pharma Pty appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Organon Pharma Pty develop or market?

  We link 6 drug profile(s) where Organon Pharma Pty is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/organon-n-v#company-drugs.

• What are the latest developments for Organon Pharma Pty?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Organon Pharma Pty focus on?

  Organon Pharma Pty focuses on Atopic Dermatitis based on our analysis of their pipeline programs and drug development activities.